Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Affiliations

• ¹ Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany. georg.lenz@ukmuenster.de.
• ² Eastern Health Clinical School, Monash University, Olivia Newton John Cancer Research and Wellness Centre, Melbourne, VIC, Australia.
• ³ University Hospitals Leuven, Leuven, Belgium.
• ⁴ Lymphoid Malignancies Unit, Groupe Hospitalier Henri Mondor-Albert Chenevier, Creteil, France.
• ⁵ National Cancer Centre Singapore and Duke-NUS Medical School, Singapore, Singapore.
• ⁶ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
• ⁷ University College London Hospitals NHS Foundation Trust, London, UK.
• ⁸ Ballarat Regional Integrated Cancer Centre, Ballarat, VIC, Australia.
• ⁹ Department of Hematology, Odense University Hospital, Odense, Denmark.
• ¹⁰ Bayer China, Beijing, China.
• ¹¹ Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA.
• ¹² Pharmaceuticals Division, Bayer AG, Berlin, Germany.
• ¹³ Hospices Civils de Lyon, Université de Lyon, Centre Hospitalier Lyon-Sud, Service d'hématologie, Lyon, France.